Complement Factor H Polymorphism and Age-Related Macular Degeneration

  title={Complement Factor H Polymorphism and Age-Related Macular Degeneration},
  author={Albert O. Edwards and Robert Ritter and Kenneth J. Abel and A. Manning and Carolien I. M. Panhuysen and Lindsay A. Farrer},
  pages={421 - 424}
Age-related macular degeneration (AMD) is a common, late-onset, and complex trait with multiple risk factors. Concentrating on a region harboring a locus for AMD on 1q25-31, the ARMD1 locus, we tested single-nucleotide polymorphisms for association with AMD in two independent case-control populations. Significant association (P = 4.95 × 10-10) was identified within the regulation of complement activation locus and was centered over a tyrosine-402 → histidine-402 protein polymorphism in the gene… Expand

Paper Mentions

Interventional Clinical Trial
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients. GA is an advanced… Expand
ConditionsAge-Related Macular Degeneration, Geographic Atrophy
Multilocus analysis of age-related macular degeneration
This study validates the complement pathway's involvement in AMD and suggests that allelic variants in complement genes have a direct role in disease. Expand
The role of molecular genetic factors in age-related macular degeneration.
The purpose of this review is to provide an extensive report of the current data of AMD genetics and the contribution of this knowledge helps to the better understanding of its pathophysiology. Expand
Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration.
Likelihood ratio testing and conditional analyses in the case-control data set suggest that a weaker, independent protective effect exists for CC2 E318D, while polymorphisms in CC2 and CFB were strongly associated with decreased risk of AMD. Expand
Complement C3 variant and the risk of age-related macular degeneration.
The common functional polymorphism rs2230199 in the C3 gene, corresponding to the electrophoretic variants C3S and C3F, was strongly associated with age-related macular degeneration in both the English group and the Scottish group and underscores the influence of the complement pathway in the pathogenesis of this disease. Expand
Genetic variation in complement regulators and susceptibility to age-related macular degeneration
There was no evidence of association between AMD and any of the SNPs typed in CFP, CD46, CD55 or CD59, which suggests that these are not important susceptibility genes for AMD. Expand
Haplotypes in the Complement Factor H (CFH) Gene: Associations with Drusen and Advanced Age-Related Macular Degeneration
Evidence is provided that the CFH gene is associated with drusen as well as with advanced AMD, and novel susceptibility and protective haplotypes in the AMD populations are identified. Expand
An update on the genetics of age-related macular degeneration
Variants within CFH and LOC387715/HTRA1 may contribute to the increased risk of late AMD largely through their impact on precursors, such as drusen and/or other RPE/Bruch's membrane changes. Expand
Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients.
The allele frequency of Y402H polymorphism in CFH has an ethnic variation, with much lower 1277C frequency in Chinese than in white patients, despite this, the polymorphism is significantly associated with neovascular AMD in the Chinese population. Expand
Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration.
A relevant role of CFHR1 in the pathogenesis of AMD is supported and a peculiar genotype-phenotype correlation between theCFHR1 alleles and different diseases is illustrated, which may have important implications for understanding the pathophysiology of AMD. Expand
Genetics and age-related macular degeneration: a practical review for the clinician
The bulk of the available peer-reviewed evidence suggests that genetic testing is more useful as a research tool than for clinical management of patients. Expand